These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

69 related articles for article (PubMed ID: 21122642)

  • 1. Prevention of atherothrombotic disease (ATD).
    Feeman WE
    J Clin Lipidol; 2010; 4(2):136-7; author reply 137. PubMed ID: 21122642
    [No Abstract]   [Full Text] [Related]  

  • 2. Homocysteine hypothesis for atherothrombotic cardiovascular disease: not validated.
    Kaul S; Zadeh AA; Shah PK
    J Am Coll Cardiol; 2006 Sep; 48(5):914-23. PubMed ID: 16949480
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dual antiplatelet therapy in the secondary prevention of atherothrombosis: need for new therapeutic approaches.
    Sabatier B; Trinquart L; Emmerich J
    Arch Cardiovasc Dis; 2010 Oct; 103(10):497-501. PubMed ID: 21130962
    [No Abstract]   [Full Text] [Related]  

  • 4. Physical fitness and the relationship between hypertension and markers of atherothrombosis.
    Jessani S; Lip GY
    Am J Hypertens; 2007 Jun; 20(6):676-7. PubMed ID: 17531927
    [No Abstract]   [Full Text] [Related]  

  • 5. [Introduction. Residual atherothrombotic risk. Does it exist?].
    Tavazzi L; Ambrosio G
    G Ital Cardiol (Rome); 2008 Apr; 9(4 Suppl 1):3S-5S. PubMed ID: 18773745
    [No Abstract]   [Full Text] [Related]  

  • 6. Secondary prevention strategy of cardiovascular disease using endothelial function testing.
    Matsuzawa Y; Guddeti RR; Kwon TG; Lerman LO; Lerman A
    Circ J; 2015; 79(4):685-94. PubMed ID: 25740088
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Risk factor control in peripheral arterial disease can be improved. Registry study of secondary prophylactic drug therapy].
    Alhadad A; Wiktorsson C; Lindblad B; Gottsäter A
    Lakartidningen; 2010 Sep 29-Oct 5; 107(39):2322-5. PubMed ID: 20973248
    [No Abstract]   [Full Text] [Related]  

  • 8. Homocysteine-lowering therapy for preventing atherothrombotic events: its role in high risk population.
    Acikel S; Dogan M; Akdemir R
    Int J Cardiol; 2010 Oct; 144(2):326-8. PubMed ID: 19324433
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lipoprotein(a) and secondary prevention of atherothrombotic events: A critical appraisal.
    Boffa MB; Stranges S; Klar N; Moriarty PM; Watts GF; Koschinsky ML
    J Clin Lipidol; 2018; 12(6):1358-1366. PubMed ID: 30316749
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High-sensitivity C-reactive protein is only weakly related to cardiovascular damage after adjustment for traditional cardiovascular risk factors.
    Olsen MH; Christensen MK; Hansen TW; Gustafsson F; Rasmussen S; Wachtell K; Borch-Johnsen K; Ibsen H; Jørgensen T; Hildebrandt P
    J Hypertens; 2006 Apr; 24(4):655-61. PubMed ID: 16531793
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Coronary risk factors and myocardial perfusion in asymptomatic adults: the Multi-Ethnic Study of Atherosclerosis (MESA).
    Wang L; Jerosch-Herold M; Jacobs DR; Shahar E; Folsom AR
    J Am Coll Cardiol; 2006 Feb; 47(3):565-72. PubMed ID: 16458137
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The altered homeostatic theory: A hypothesis proposed to be useful in understanding and preventing ischemic heart disease, hypertension, and diabetes--including reducing the risk of age and atherosclerosis.
    Hellstrom HR
    Med Hypotheses; 2007; 68(2):415-33. PubMed ID: 16828234
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Is homocysteine a risk factor for atherothrombotic cardiovascular disease?
    Akhtar N
    J Am Coll Cardiol; 2007 Mar; 49(12):1370-1; author reply 1371. PubMed ID: 17394973
    [No Abstract]   [Full Text] [Related]  

  • 14. Pulse pressure, aortic regurgitation and carotid atherosclerosis: a comparison between hypertensives and normotensives.
    Su TC; Chien KL; Jeng JS; Chang CJ; Hsu HC; Chen MF; Sung FC; Lee YT
    Int J Clin Pract; 2006 Feb; 60(2):134-40. PubMed ID: 16451282
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum osteoprotegerin levels in patients with acute atherothrombotic stroke and lacunar infarct.
    Guldiken B; Guldiken S; Turgut B; Turgut N; Demir M; Celik Y; Arikan E; Tugrul A
    Thromb Res; 2007; 120(4):511-6. PubMed ID: 17258300
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Prevention of coronary disease in clinical practice. Guidelines of the Task Force of the European Society of Cardiology, European Atherosclerosis Society and European Society of Hypertension].
    Pyorala K; De Backer G; Graham I; Poole-wilson P; Wood D
    G Ital Cardiol; 1996 Feb; 26(2):127-68. PubMed ID: 8666173
    [No Abstract]   [Full Text] [Related]  

  • 17. Atherothrombotic comorbidity in the rheumatic diseases. The evidence becomes clearer. What should clinicians do?
    Del Rincón I
    Arthritis Rheum; 2009 Oct; 61(10):1284-6. PubMed ID: 19790116
    [No Abstract]   [Full Text] [Related]  

  • 18. Late thrombosis of saphenous vein coronary bypass grafts related to risk factors.
    Solymoss BC; Nadeau P; Millette D; Campeau L
    Circulation; 1988 Sep; 78(3 Pt 2):I140-3. PubMed ID: 3261650
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cardiovascular disease is preventable among women.
    Kuller LH
    Expert Rev Cardiovasc Ther; 2010 Feb; 8(2):175-87. PubMed ID: 20136604
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Peripheral vascular disease and risk factors of atherosclerosis: an epidemiologic study.
    Cavallo-Perin P; Barile C; Ozzello A; La Rosa M; Pagano G; Lenti G
    Panminerva Med; 1984; 26(3):139-43. PubMed ID: 6522074
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.